Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients

Vascular Pharmacology

Volumn 47, Issue 2-3, 2007, Pages 118-124

  Maiti, Rituparna ^a   Agrawal, N K ^a   Dash, D ^a   Pandey, B L ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Atherosclerosis; Inflammation; Pentoxifylline; Type 2 diabetes mellitus

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUTATHIONE; MALONALDEHYDE; METFORMIN; PENTOXIFYLLINE; SERUM ALBUMIN; SULFONYLUREA;

ADD ON THERAPY; ADULT; ANTHROPOMETRY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOT RETRACTION; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; EX VIVO STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INFLAMMATION; INFORMED CONSENT; LEUKOCYTE COUNT; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STANDARD; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION; TREATMENT OUTCOME;

ATHEROSCLEROSIS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CLOT RETRACTION; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTATHIONE; HUMANS; HYPERTENSION; INFLAMMATION; LEUKOCYTE COUNT; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION; SERUM ALBUMIN;

EID: 34447650212     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2007.05.004     Document Type: Article

References (70)

1. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
2. Ambrus J.L., Ambrus C.M., and Gastpar H. Studies on platelet aggregation with Pentoxifylline: effect in neoplastic disorders and other new indications. J. Med. 10 5 (1979) 339-345
3. Baeyer H.V., Hopfenmuller W., Riedel E., and Affeld K. Atherosclerosis: current concepts of pathophysiology and pharmacological intervention based on trial outcomes. Clin. Nephro. 60 (2003) S31-S48
4. Barzilay J.I., Abraham L., Heckbert S.R., Cushman M., Kuller L.H., Resnick H.E., and Tracy R.P. The relation of markers of inflammation to the development of glucose disorders in the elderly: the cardiovascular health study. Diabetes 50 (2001) 2384-2389
5. Beermann B., Ings R., Mansby J., Chamberlain J., and McDonald A. Kinetics of intravenous and oral Pentoxifylline in healthy subjects. Clin. Pharmacol. Ther. 37 1 (1985) 25-28
6. Beutler E., Duron O., and Kelly B.M. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 61 5 (1963) 882-888
7. Black S., Kushner I., and Samols D. C-reactive protein. J. Biol. Chem. 279 47 (2004) 48487-48490
8. Chan K.Y., Boucher E.S., Gandhi P.J., and Silva M.A. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am. J. Health-Syst. Pharm. 61 16 (2004) 1676-1681
9. Colowick S.P., and Kaplan N.O. Methods in Enzymology vol. LII (Part C) (1978), Academic Press, Inc., London
10. Cybulsky M.I., and Gimbrone Jr. M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251 (1991) 788-791
11. Dandona P., Kumar V., Aljada A., Ghanim H., Syed T., Hofmayer D., Mohanty P., Tripathy D., and Garg R. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action. J Clin. Endocrinol. Metab. 88 9 (2003) 4496-4501
12. Danesh J., Collins R., Appleby P., and Peto R. Association of fibrinogen, CRP, albumin, or leukocyte counts with CHD. JAMA 279 (1998) 1477-1482
13. Duncan B.B., Schmidt M.I., Pankow J.S., Ballantyne C.M., Couper D., Vigo A., Hoogeveen R., Folsom A.R., and Heiss G. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52 (2003) 1799-1805
14. Ely H. Is Pentoxifylline the drug of the decade?. J. Am. Acad. Dermatol. 30 4 (1994) 639-642
15. Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., Quagliaro L., Ceriello A., and Giugliano D. Inflammatory cytokines concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106 (2002) 2067-2072
16. Fluckiger R., and Winterhalter K.H. In vitro synthesis of hemoglobin A1C. FEBS Lett. 71 (1976) 356-360
17. Ford E.S. Leukocyte count, ESR, and diabetes incidence in a national sample of US adults. Am. J. Epidemiol. 155 (2002) 57-64
18. Gonzalez A.R., Portales-Perez D., Baranda L., Redondo J.M., Martinez-Martinez S., Yanez-Mo M., Garcia-Vicuna R., Cabanas C., and Sanchez-Madrid F. Pentoxifylline inhibits adhesion and activation of human T-lymphocytes. J. Immunol. 161 (1998) 65-72
19. Grundy S.M., Pasternak R., Greenland P., Smith S., and Fuster V. Assessment of cardiovascular risk by use of multiple risk factor assessment equations. Circulation 100 (1999) 1481-1492
20. Haley K.J., Lilly C.M., Yang J.H., Feng Y., Kennedy S.P., Turi T.G., Thompson J.F., Sukhova G.H., Libby P., and Lee R.T. Overexpression of Eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify the potential novel pathway. Circulation 102 (2000) 2185-2189
21. Iyer P.D., and Krishnaswamy P.R. A chemical method for the estimation of total glycosylated hemoglobin-A in diabetes mellitus. Bull. Jaslok. Hosp. Res. Cent. 5 (1980) 17-19
22. Jarret R.J., and Shipley M.J. Type 2 diabetes mellitus and cardiovascular disease: putative association via common antecedents - further evidence from the Whitehall Study. Diabetologia 31 (1988) 737-740
23. Ji Q., Zhang L., Jia H., Yang J., and Xu J. Pentoxifylline inhibits endotoxin-induced NF-κB activation and associated production of pro-inflammatory cytokines. Ann. Clin. Lab. Sci. 34 (2004) 427-436
24. Kereiakes D.J. The fire that burns within: C-reactive protein. Circulation 107 (2003) 373-374
25. Khaw K.T., Wareham N., Luben R., Bingham S., Oakes S., Welch A., and Day N. Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322 (2001) 15-18
26. King D.E., Mainous A.G., Buchanan T.A., and Pearson W.S. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 26 (2003) 1535-1539
27. King P., Peacock I., and Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br. J. Clin. Pharmacol. 48 5 (1999) 43-48
28. Koya D., and King G.I. Protein kinase C activation and the development of diabetic complications. Diabetes 47 (1998) 859-866
29. Kullo I.J., and Gersh B.J. Markers of inflammation and thrombosis: clues to plaque instability?. Am. Heart J. 45 (2003) 941-942
30. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus: the Finnish studies. Ann. Intern. Med. 124 (1996) 127-130
31. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
32. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 135-143
33. Luis A.J. Atherosclerosis. Nature 407 (2000) 233-241
34. Meiners I., Auschildt S., Nieber K., and Munch G. Pentoxifylline and propentoxifylline are inhibitors of TNF-alfa release in monocytes activated by advanced glycation end products. J. Neural Transm. 111 (2004) 441-447
35. Michael B. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
36. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., and Dandona P. Evidence for a potent anti-inflammatory effect of Rosiglitazone. J. Clin. Endocrinol. Metab. 89 6 (2004) 2728-2735
37. Mulvihill N.T., and Foley J.B. Inflammation in acute coronary syndrome. Heart 87 (2002) 201-204
38. Nakanishi N., Yoshida H., Matsuo Y., Suzuki K., and Tatara K. White blood cell count and the risk of impaired fasting glucose or type 2 diabetes mellitus in middle aged Japanese men. Diabetologia 45 (2002) 42-48
39. Navarro J.F., Mora C., Rivero A., Gallego E., Chahin J., Macia M., Mendez M.M., and Garcia J. Urinary protein excretion and serum Tumor Necrosis Factor in diabetic patients with advanced renal failure: effects of Pentoxifylline administration. Am. J. Kidney Dis. 33 3 (1999) 458-463
40. Navarro J.F., Mora C., Muros M., Macia M., and Garcia J. Effects of Pentoxifylline administration on urinary N-acetyl-β-glucosaminidase excretion in type 2 diabetes patients: a short-term, prospective, randomized study. Am. J. Kidney Dis. 42 2 (2003) 264-270
41. Nayak S.S., and Pattabiraman T.N. A new colorimetric method for the estimation of glycosylated hemoglobin. Clin. Chim. Acta 109 (1981) 267-274
42. Oxford Centre for Diabetes, Endocrinology and Metabolism. Diabetes Trial Unit (2006). http://www.dtu.ox.ac.uk/index.html?maindoc=/riskengine/index.html Accessed August 4, 2006
43. Pasceri V., Willerson J.T., and Yeh E.T. Direct pro-inflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
44. Pickup J.C., and Crook M.A. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia 41 (1998) 1241-1248
45. Poulakis N., Androutsos G., Kazi D., Bastas A., Provata A., Bitsakou C., Kontozoglou T., Polyzogopoulou C., and Tassiopoulou A. The differential effect of Pentoxifylline on cytokine production by alveolar macrophages and its clinical implications. Respir. Med. 93 (1999) 52-57
46. Ramachandran A., Snehalatha C., Satyavani K., Sivasankari S., and Vijay V. Metabolic syndrome in urban Asian Indian adults - a population study using modified ATP III criteria. Diabetes Res. Clin. Pract. 60 3 (2003) 199-204
47. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
48. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular diseases. N. Engl. J. Med. 342 (2000) 836-843
49. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-125
50. Schandene L., Vandenbussche P., Crusiaux A., Alegre M.L., Abramowicz D., Dupont E., Content J., and Goldman M. Differential effect of Pentoxifylline on the production of TNF-α and IL-6 by monocytes and T-cells. Immunology 76 1 (1992) 30-34
51. Schillinger M., Exner M., Amighi J., Mlekusch W., Sabeti S., Rumpold H., Wagner O., and Minar E. Joint effect of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation 108 (2003) 2323-2328
52. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., Zhang J., Cao R., Yan S.D., Brett J., and Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of VCAM-1 in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96 (1995) 1395-1403
53. Schmidt A.M., Yan S.D., Wautier J.L., and Stern D. Activation of receptor for advanced glycation endproducts: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84 (1999) 489-497
54. Schmidt M.I., Duncan B.B., Shaarret A.R., Lindberg G., Savage P.J., Offenbacher S., Ajambuja M.I., Tracy R.P., and Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet 353 (1999) 1649-1652
55. Stern M.P. Diabetes and cardiovascular disease: the 'common soil' hypothesis. Diabetes 44 (1995) 369-374
56. Sullivan G.W., Carper H.T., Novick Jr. W.J., and Mandell G.L. Inhibition of inflammatory action of IL-1 and TNF-α on neutrophil function by Pentoxifylline. Infect. Immun. 56 7 (1988) 1722-1729
57. Szmitko P.E., Wang C.H., Weisel R.D., de Almeida J.R., Anderson T.J., and Verma S. New markers of inflammation and endothelial cell activation (part I). Circulation 108 (2003) 1917-1923
58. Szmitko P.E., Wang C.H., Weisel R.D., Jeffries G.A., Anderson T.J., and Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation (part II). Circulation 108 (2003) 2041-2048
59. Tan K.C.B., Chow W.S., and Tam S. Association between acute phase reactants and advanced glycation end products in type 2 DM. Diabetes Care 27 (2004) 223-228
60. Tong P.C., Lee K.F., So W.Y., and Ng M.H. White blood cell count is associated with macro-and microvascular complications with type 2 DM. Diabetes Care 27 (2004) 2216-2222
61. Tousoulis D., Davies G., Stefanadis C., Toutouzas P., and Ambrose J.A. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 89 (2003) 993-997
62. Tripathy K., and Prakash U. Pentoxifylline in management of proteinuria in diabetic nephropathy. Nephron 64 (1993) 641-642
63. Tripathy K., Mishra R., Agrawal J.K., and Bajpai H.S. Effect of Dipyridamole and Pentoxifylline on regression of gross proteinuria in diabetic nephropathy. JAPI 39 1 (1991) 110
64. Verma S. C-reactive protein incites atherosclerosis. Can. J. Cardiol. 20 suppl B (2004) 21B-31B
65. Verma S., Szmitko P.E., and Yeh E.T.H. C-reactive protein: structure affects function. Circulation 109 (2004) 1914-1917
66. Vozarova B., Weyer C., Lindsay R.S., Pratley R.E., Bogardus C., and Tataranni P.A. High WBC count is associated with a worsening of insulin sensitivity and predicts the development of type 2 DM. Diabetes 51 (2002) 455-461
67. Ward A., and Clissold S.P. Pentoxifylline: a review of its pharmacodynamics and pharmacokinetics properties, and its therapeutic efficacy. Drugs 34 (1987) 50-97
68. Wilson P.W.F., and Grundy S.M. The metabolic syndrome: practical guide to origins and treatment: (part I). Circulation 108 (2003) 1422-1425
69. World Health Organization. Obesity: prevalence and managing the global epidemic. Report of WHO consultation on obesity, Geneva (1997) 3-5 June
70. Yeh E.T.H., and Willerson J.T. Coming age of C-reactive protein: using inflammation markers in cardiology. Circulation 107 (2003) 370-372